Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Starting with HEPLISAV-B, net product revenue grew 69% year-on-year to $239 million in 2023, another record year for the franchise |
| So we think we're in a good position as it relates to some of those macro factors to continue to grow the vaccine market through 2024 and beyond |
| Encouragingly, we expect the market to strengthen for the remainder of Q1 into Q2 as the focus of health care providers and retail pharmacy shifted back to prioritizing non-respiratory vaccines |
| In closing, we believe that with our strong financial profile we are well-positioned to drive sustainable growth in our HEPLISAV-B business, capture majority market share and lead the expansion of the adult hepatitis B vaccine market |
| hepatitis B vaccine market is evolving due to an active winter respiratory disease season and why we continue to be very confident in another year of growth for the brand and in the long-term prospects for HEPLISAV-B in the vaccine market with one of the largest total addressable populations in the United States |
| We're excited about our recent accomplishments and the strength of our position overall |
| Importantly, our strong financial position of $742 million of cash provides us with the optionality to continue to build value across our business, such as through incremental investments to drive the HEPLISAV-B market opportunity, continuing to advance R&D efforts, and pursuing new opportunities to accelerate our growth |
| We are really proud of the way that we've been able to pull-through those on improving yields over time to realize you know sort of an estimate of approximately 80% gross margin for 2024 |
| We expect SG&A expenses to be between approximately $160 million and $180 million and we also expect to be cash flow positive from the full year ended December 31, 2024, reflecting our continued discipline towards allocating capital to drive top-line revenue growth, while thoughtfully advancing our research programs |
| In 2023, we achieved a record net product sales and market share, establishing HEPLISAV-B as the leading adult hepatitis B vaccine in the U.S |
| Additionally, we drove significant hepatitis B market growth by effectively pulling through the ACIP universal recommendation |
| Our success in 2023 reaffirms our confidence in the sizable market opportunity and long-term revenue growth potential for HEPLISAV-B |
| We are also pleased with our continued trend in the margin profile for HEPLISAV-B with gross margin of approximately 76% in 2023 consistent with our guidance of mid-70s percentage for the full year and significant improvement compared to about 68% in the prior year |
| We believe this recommendation will continue to be a significant catalyst for growth and estimate the hepatitis B vaccine market opportunity for HEPLISAV grew to approximately $525 million in 2023 on a clear path to approximately $800 million by 2027 with HEPLISAV-B achieving a majority market share by that time |
| Regarding share, actually, we're excited about our ability to continue to take market share |
| I'm pleased to report another quarter and full year of strong financial performance |
| 2023 was characterized by record revenue growth for HEPLISAV-B, delivering 69% growth year-over-year, and becoming the market leader market share leader in the two largest growth segments, which are retail pharmacies and integrated delivery networks, making HEPLISAV-B the leading vaccine in the U.S |
| The sales growth continues to be driven by HEPLISAV-B strong performance in two critical segments, retail pharmacy and integrated delivery networks or IDNs |
| And so Kelly why don't you provide some commentary on our overall capital allocation strategy? Kelly MacDonald Sure/ So our exceptional commercial execution for HEPLISAV-B along with our hydrogen supply business of course has created this strengthening of our financial profile |
| We certainly believe that strong position will help us drive further growth including first and foremost looking for opportunities to invest in driving growth in HEPLISAV-B as well as advancing our organic clinical stage assets as well as our preclinical portfolio |
| Our continued interactions with our customers are incredibly positive |
| Customers continue to respond positively to the ACIP change and recognize the need to adopt and implement the recommendations |
| One of the unique advantages we believe of our CpG 1018 adjuvant is it safety and tolerability profile combined with its ability to induce strong CD4 positive T-cell responses which we believe are critical to preventing the reactivation of Zoster Virus |
| We are extremely confident in the long-term expansion of the U.S |
| We are very proud of our commercial team's execution and encouraged by the progress and momentum for HEPLISAV-B establishing a majority market share in the key segments of Retail Pharmacy and IDN |
| In summary, we had a tremendous 2023, reaffirming our confidence that HEPLISAV-B will strengthen its position as the clear market leader in the expanding hepatitis B vaccine market |
| So we also had fairly successful growth in market share throughout the year |
| So we like our position and our ability to take market share in this first quarter, even with the market being what it is |
| Currently, there's a successful licensed vaccine on the market, but we believe there's an opportunity to develop an improved vaccine, given the challenging tolerability profile of the current market leading product |
| hepatitis B vaccine market and forecast annual market growth of approximately 10% to 15% over the next several years with HEPLISAV-B gaining meaningful increases in total market share over that time |
| Statement |
|---|
| Due to softness in January, we anticipate little to no growth in the hepatitis B vaccine market for Q1, as compared to Q4 2023 |
| Based on feedback from customers cough, cold and flu season has extended much further into January than expected reducing the number of wellness visits and vaccination opportunities |
| I wanted to drill down a little bit into that comment you made on little growth in the Hep B market in Q1 |
| I have a question about the – on the effect that you described from the longer than expected respiratory vaccine season and the Q4 seasonality |
Please consider a small donation if you think this website provides you with relevant information